Abstract
Meeting abstracts Tremelimumab is a fully human monoclonal antibody that binds to CTLA-4 expressed on the surface of activated T lymphocytes and results in inhibition of B7-CTLA-4-mediated down regulation of T cell activation. Both transcatheter arterial chemoembolization (TACE) and radiofrequency
Highlights
Tremelimumab is a fully human monoclonal antibody that binds to CTLA-4 expressed on the surface of activated T lymphocytes and results in inhibition of B7CTLA-4-mediated down regulation of T cell activation
Both transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) have been shown to induce a peripheral immune response which may enhance the effect of anti-CTLA4 treatment in patients with advanced hepatocellular carcinoma (HCC)
Tumor tissue is collected for analysis at baseline on all patients with optional on-treatment tumor biopsies performed at the time of the radiologic procedure
Summary
Paired tumor biopsy analysis and safety data from a pilot study evaluating Tremelimumab - a monoclonal antibody against CTLA-4 - in combination with ablative therapy in patients with hepatocellular carcinoma (HCC). Austin Duffy1*, Sid P Kerkar, David E Kleiner, Susanna Ulahannan, Metin Kurtoglu, Oxana Rusher, Suzanne Fioravanti, Melissa Walker, William D Figg, Kathryn Compton, Aradhana Venkatesan, Nadine Abi-Jaoudeh, Brad Wood, Tim F Greten. From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. 6-9 November 2014
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
